Clinical symptom scores after injection of intact monoclonal antibody 35 (mAb35). The score in the severe myasthenia gravis (MG) group was significantly higher at 18 to 36 h after mAb35 injection than that in the moderate MG group (P < 0.017), and the scores in the moderate and severe MG groups were significantly higher at 6 to 48 h after mAb35 injection than that in the sham group (P < 0.01, each). The clinical symptoms were expressed as follows: 0, no clinical symptoms; 1, first signs of grasp weakness after a few trials; 2, incomplete paralysis of hind limbs; 3, hind limbs paralyzed and unable to stand; 4, moribund; and 5, dead. n = 10 in each group. *P < 0.01 versus sham group, †P < 0.017 versus the moderate MG group. Data were analyzed using Friedman test followed by Wilcoxon test to evaluate the significant effect of time and Kruskal–Wallis test followed by Dunn test to compare the three groups at each time point with Bonferroni correction for multiple comparisons.